|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2004-4-28
|
|
pubmed:abstractText |
The administration of alemtuzumab (Campath-1H [C1H]; Berlex Laboratories, Montville, NJ) at transplantation prevents a vigorous immune response and is believed to allow a gradual engagement of the host immune system. We report our preliminary experience with C1H and tacrolimus (Tac) immunosuppression in adult liver transplantation.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Steroids,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus,
http://linkedlifedata.com/resource/pubmed/chemical/alemtuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0041-1337
|
|
pubmed:author |
pubmed-author:De FariaWervistonW,
pubmed-author:EsquenaziVioletV,
pubmed-author:GaynorJeffrey JJJ,
pubmed-author:KatoTomoakiT,
pubmed-author:LeviDavid MDM,
pubmed-author:MadariagaJuan RJR,
pubmed-author:MillerJoshuaJ,
pubmed-author:NishidaSeigoS,
pubmed-author:RegevArieA,
pubmed-author:RuizPhillipP,
pubmed-author:TryphonopoulosPanagiotisP,
pubmed-author:TzakisAndreas GAG,
pubmed-author:WepplerDebbieD
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
27
|
|
pubmed:volume |
77
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1209-14
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15114087-Acute Disease,
pubmed-meshheading:15114087-Adult,
pubmed-meshheading:15114087-Antibodies, Monoclonal,
pubmed-meshheading:15114087-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15114087-Antibodies, Neoplasm,
pubmed-meshheading:15114087-Female,
pubmed-meshheading:15114087-Graft Rejection,
pubmed-meshheading:15114087-Humans,
pubmed-meshheading:15114087-Immunosuppressive Agents,
pubmed-meshheading:15114087-Kidney,
pubmed-meshheading:15114087-Liver Transplantation,
pubmed-meshheading:15114087-Male,
pubmed-meshheading:15114087-Retrospective Studies,
pubmed-meshheading:15114087-Steroids,
pubmed-meshheading:15114087-Tacrolimus,
pubmed-meshheading:15114087-Time Factors
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation.
|
|
pubmed:affiliation |
Department of Surgery, Division of Transplantation, University of Miami School of Medicine, Miami, Florida 33136, USA. atzakis@med.miami.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|
